DK3448416T3 - Semaglutid ved kardiovaskulære tilstande - Google Patents

Semaglutid ved kardiovaskulære tilstande Download PDF

Info

Publication number
DK3448416T3
DK3448416T3 DK17721109.1T DK17721109T DK3448416T3 DK 3448416 T3 DK3448416 T3 DK 3448416T3 DK 17721109 T DK17721109 T DK 17721109T DK 3448416 T3 DK3448416 T3 DK 3448416T3
Authority
DK
Denmark
Prior art keywords
semaglutid
cardiovascular conditions
cardiovascular
conditions
Prior art date
Application number
DK17721109.1T
Other languages
Danish (da)
English (en)
Inventor
Oluf Kristian Højbjerg Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3448416(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK3448416T3 publication Critical patent/DK3448416T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
DK17721109.1T 2016-04-28 2017-04-28 Semaglutid ved kardiovaskulære tilstande DK3448416T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
DK3448416T3 true DK3448416T3 (da) 2022-10-03

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17721109.1T DK3448416T3 (da) 2016-04-28 2017-04-28 Semaglutid ved kardiovaskulære tilstande

Country Status (24)

Country Link
US (3) US20190134162A1 (cg-RX-API-DMAC7.html)
EP (1) EP3448416B1 (cg-RX-API-DMAC7.html)
JP (1) JP7221694B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250038818A (cg-RX-API-DMAC7.html)
CN (1) CN109069589B (cg-RX-API-DMAC7.html)
AU (2) AU2017256774B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072020A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022535A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003045A1 (cg-RX-API-DMAC7.html)
DK (1) DK3448416T3 (cg-RX-API-DMAC7.html)
ES (1) ES2928007T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221150T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060040T2 (cg-RX-API-DMAC7.html)
IL (1) IL262390B1 (cg-RX-API-DMAC7.html)
MA (1) MA44762A (cg-RX-API-DMAC7.html)
MX (1) MX2018012700A (cg-RX-API-DMAC7.html)
MY (1) MY202967A (cg-RX-API-DMAC7.html)
PH (1) PH12018502274B1 (cg-RX-API-DMAC7.html)
PL (1) PL3448416T3 (cg-RX-API-DMAC7.html)
RS (1) RS63630B1 (cg-RX-API-DMAC7.html)
RU (1) RU2768283C2 (cg-RX-API-DMAC7.html)
SI (1) SI3448416T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017186896A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202507395B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768283C2 (ru) * 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
HRP20230929T1 (hr) * 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
ES2994462T3 (en) * 2018-12-21 2025-01-24 Novo Nordisk As Process of spray drying of glp-1 peptide
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN107961377B (zh) * 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
PT2651398T (pt) * 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6126097B2 (ja) * 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
RU2768283C2 (ru) 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях

Also Published As

Publication number Publication date
BR112018072020A2 (pt) 2019-02-12
AU2017256774B2 (en) 2024-07-11
RU2018140900A (ru) 2020-05-28
MA44762A (fr) 2019-03-06
KR102778218B1 (ko) 2025-03-10
JP2019514925A (ja) 2019-06-06
EP3448416A1 (en) 2019-03-06
AU2017256774A1 (en) 2018-11-01
MY202967A (en) 2024-05-31
RS63630B1 (sr) 2022-10-31
PH12018502274B1 (en) 2024-02-28
WO2017186896A1 (en) 2017-11-02
MX2018012700A (es) 2019-01-30
KR20180135012A (ko) 2018-12-19
PH12018502274A1 (en) 2019-09-09
CA3022535A1 (en) 2017-11-02
US20250262281A1 (en) 2025-08-21
KR20250038818A (ko) 2025-03-19
RU2768283C2 (ru) 2022-03-23
HUE060040T2 (hu) 2023-01-28
SI3448416T1 (sl) 2022-10-28
CN109069589A (zh) 2018-12-21
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
ZA202507395B (en) 2025-09-25
KR20220147712A (ko) 2022-11-03
CN109069589B (zh) 2022-09-06
JP7221694B2 (ja) 2023-02-14
RU2018140900A3 (cg-RX-API-DMAC7.html) 2020-09-28
PL3448416T3 (pl) 2022-11-07
ES2928007T3 (es) 2022-11-14
ZA202507394B (en) 2025-09-25
IL262390A (en) 2018-12-31
HRP20221150T1 (hr) 2022-11-25
US20250288649A1 (en) 2025-09-18
CL2018003045A1 (es) 2018-12-14
EP3448416B1 (en) 2022-08-10
AU2024227113A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
EP3374114A4 (en) WORKBENCH
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
DK3305788T3 (da) Janus-kinase-hæmmer
DK3331529T3 (da) Muskarinagonister
DK3448416T3 (da) Semaglutid ved kardiovaskulære tilstande
DK3310450T3 (da) Olie-vand-separator
EP3341259A4 (en) WHEELBARROW
DK3242685T3 (da) Cxcr4-bindende molekyler
DK3270930T3 (da) Præeklampsi
DK3292136T3 (da) Penicillin-g-acylaser
DK3551355T3 (da) Immobiliseret indsats
DE112015006486A5 (de) Inkubationsrinne
DE112016001806A5 (de) Bausatz
DK3253755T3 (da) Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
DK3274482T3 (da) Stenborsknop
DE102015206660A8 (de) Plattenaufteilanlage
DK3318308T3 (da) Badmintonketsjer
DK3423082T3 (da) Liraglutid ved kardiovaskulære tilstande
DE112015005898A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill
UY4439S (es) Trofeo
DE102015000551A8 (de) Rotationszerstäuberturbine
DK3334807T3 (da) Ildtænder